ANI Pharmaceuticals ANIP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $92.15M+538% | $78.34M+523% | $40.57M+672% | -$10.21M-138% | -$21.05M-159% | ||
| $89.45M+17.8% | $91.42M+35.0% | $91.4M+51.5% | $84.52M+41.4% | $75.94M+27.0% | ||
| $39.25M+25.5% | $37.93M+29.3% | $35.22M+26.2% | $33.02M+27.7% | $31.28M+34.5% | ||
| $20.14M+171% | $14.24M+165% | -$5.65M+55.6% | -$30.04M-189% | -$28.4M-202% | ||
| $1.39M+60.9% | $1.36M+111% | $1.33M+4.5% | $1.11M-48.3% | $864K-71.6% | ||
| $34.78M— | $58.53M— | $56.19M— | $20.78M— | —— | ||
| —— | —— | $10.37M-58.9% | $8.57M-59.4% | $19.27M+89.2% | ||
| —— | —— | —— | —— | —— | ||
| -$1.61M— | $5.02M— | —— | —— | —— | ||
| -$9.36M— | -$16M— | —— | —— | —— | ||
| $9.5M— | $2.82M— | —— | —— | —— | ||
| $1.76M+9.7% | $1.76M+15.3% | $1.6M+5.3% | $1.62M-17.2% | $1.61M-2.3% | ||
| $208.61M+158% | $185.23M+189% | $170.72M+83.8% | $139.14M+23.6% | $80.74M-30.3% | ||
| $17.44M+23.4% | $13.84M-14.8% | $14.99M-7.0% | $13.69M+5.0% | $14.13M+27.3% | ||
| $8.36M-53.8% | $20.49M+2,757% | $20.41M+552% | $20.98M+295% | $18.09M+87.7% | ||
| -$25.8M+94.0% | -$34.32M+91.5% | -$43.6M+89.1% | -$435.96M-8,893% | -$433.5M-5,900% | ||
| $751K-53.8% | $1.16M-28.8% | $1.56M-3.8% | $1.63M0.0% | $1.63M0.0% | ||
| $21.96M+78.5% | $12.21M+11.4% | $11.92M+9.6% | $11.55M+6.4% | $12.3M+21.8% | ||
| $2.03M-99.3% | $0-100% | $297.09M+19,706% | $295.06M— | $293.78M— | ||
| -$332K-482% | $0— | $13.57M— | $3.78M— | -$57K— | ||
| —— | —— | —— | $279.38M— | $279.67M— | ||
| $220K+129% | -$233K+50.4% | $725K+1,067% | $74K— | -$767K— | ||
| $161.38M+305% | $140.73M+285% | $117.63M+345% | -$22.28M-128% | -$78.76M-149% | ||
| $25.86M+2.1% | $26.93M+10.5% | $27.47M+0.8% | $22.09M-31.3% | $25.33M-27.8% | ||
| $11.32M-38.8% | $17.67M-7.3% | $18.46M+5.4% | $18.33M+0.2% | $18.49M— | ||
| $1.39M+60.9% | $1.36M+111% | $1.33M+4.5% | $1.11M-48.3% | $864K-71.6% | ||
| -$20.38M-59.2% | -$32.29M-5,116% | -$28.46M-973% | -$13.16M-10,776% | -$12.8M-2,406% | ||
| $15.77M+23.7% | $24.44M+297% | $25.95M+20,376% | $20.16M— | $12.75M— | ||
| -$1.61M— | $5.02M— | —— | —— | —— | ||
| $1.09M-88.0% | $10.73M+17.9% | $15.54M+513% | $14.29M— | $9.12M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $4.38M+220% | ||
| $1.76M+9.7% | $1.76M+15.3% | $1.6M+5.3% | $1.62M-17.2% | $1.61M-2.3% | ||
| $89.45M+17.8% | $91.42M+35.0% | $91.4M+51.5% | $84.52M+41.4% | $75.94M+27.0% | ||
| $8.36M-53.8% | $20.49M+2,757% | $20.41M+552% | $20.98M+295% | $18.09M+87.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $191.17M+187% | $171.39M+259% | $155.73M+103% | $125.44M+26.0% | $66.61M-36.4% | ||
| $191.17M+187% | $171.39M+259% | $155.73M+103% | $125.44M+26.0% | $66.61M-36.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ANI Pharmaceuticals generate?
- ANI Pharmaceuticals (ANIP) generated $208.6M in operating cash flow over the trailing twelve months.
- What is ANI Pharmaceuticals's free cash flow?
- After $17.4M of capital expenditures, ANI Pharmaceuticals's free cash flow was $191.2M over the trailing twelve months, up 187.0% year over year.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
